Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.

Bispecific antibodies: a mechanistic review of the pipeline

Abstract

The term bispecific antibody (bsAb) is used to describe a large family of molecules designed to recognize two different epitopes or antigens. BsAbs come in many formats, ranging from relatively small proteins, merely consisting of two linked antigen-binding fragments, to large immunoglobulin G (IgG)-like molecules with additional domains attached. An attractive bsAb feature is their potential for novel functionalities - that is, activities that do not exist in mixtures of the parental or reference antibodies. In these so-called obligate bsAbs, the physical linkage of the two binding specificities creates a dependency that can be temporal, with binding events occurring sequentially, or spatial, with binding events occurring simultaneously, such as in linking an effector to a target cell. To date, more than 20 different commercialized technology platforms are available for bsAb creation and development, 2 bsAbs are marketed and over 85 are in clinical development. Here, we review the current bsAb landscape from a mechanistic perspective, including a comprehensive overview of the pipeline.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41573-019-0028-1

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 216 references

Research works printed but not linked: 5

  1. Chames, P. & Baty, D. Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Devel. 12, 276–283 (2009).
  2. Tibben, J. G. et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab’)2 in ovarian carcinoma patients. Int. J. Cancer 66, 477–483 (1996). · DOI
  3. Bortoletto, N., Scotet, E., Myamoto, Y., D’Oro, U. & Lanzavecchia, A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur. J. Immunol. 32, 3102–3107 (2002). · doi:10.1002/1521-4141(200211)32:11<3102::aid-immu3102>3.0.co;2-c
  4. Pfosser, A., Brandl, M., Salih, H., Grosse-Hovest, L. & Jung, G. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int. J. Cancer 80, 612–616 (1999). · doi:10.1002/(sici)1097-0215(19990209)80:4<612::aid-ijc21>3.0.co;2-k
  5. Topp, M. S. et al. Safety and preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies. Blood 130, 1495 (2017).

Cited by

See all 1,303

Metadata

Authors
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I.
Affiliations
  • Genmab (Netherlands) (NL)
  • Leiden University Medical Center (NL)
Corresponding author
Parren, Paul W. H. I.
Venue
Nature Reviews Drug Discovery
Published
2019-06-07
Volume
18
Issue
8
Pages
585-608
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2948141873
Cited by
1,303
References
216
Citations by year
2026: 180 · 2025: 184 · 2024: 208 · 2023: 187 · 2022: 183 · 2021: 201 · 2020: 127 · 2019: 32
FWCI
20.48
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
bispecific antibodies, antibody-drug conjugates, effector function
MeSH terms
Animals, Binding Sites, Antibody, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Drug Design, Antibodies, Bispecific, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bispecific antibodies: a mechanistic review of the pipeline. https://app.cochat.ai/papers/10.1038/s41573-019-0028-1
The paper
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019). Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-019-0028-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.